Himmelmann A, Thevenin C, Harrison K, Kehrl J H
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-1876, USA.
Blood. 1996 Feb 1;87(3):1036-44.
The gene defective in X-linked agammaglobulinemia (XLA) encodes a novel protein kinase termed Bruton's tyrosine kinase (Btk). Whereas the XLA phenotype is confined to abnormalities of B-cell development and function, Btk is expressed not only in B-lymphocyte lineage but also in myeloid lineage cells. The first 450 basepairs of the Btk promoter fused to a luciferase gene displayed a similar cell-type specificity. Critical binding sites for the transcription factors PU.1 and Sp1 were identified in the proximal portion of the Btk promoter upstream of a cluster of transcriptional start sites. Mutation of either the PU.1 or Sp1 site markedly reduced the activity of a Btk promoter-luciferase reporter construct in transfection experiments. In addition, PU.1 directly transactivated the Btk promoter, and deletion of the PU.1 binding site abolished this effect. This study implicates PU.1 and Sp1 as major regulators of Btk expression and provides a foundation for further study of the regulation of this gene in XLA patients that lack Btk mRNA.
X连锁无丙种球蛋白血症(XLA)中的缺陷基因编码一种名为布鲁顿酪氨酸激酶(Btk)的新型蛋白激酶。虽然XLA的表型仅限于B细胞发育和功能异常,但Btk不仅在B淋巴细胞谱系中表达,也在髓系谱系细胞中表达。与荧光素酶基因融合的Btk启动子的前450个碱基对显示出类似的细胞类型特异性。在转录起始位点簇上游的Btk启动子近端部分鉴定出转录因子PU.1和Sp1的关键结合位点。在转染实验中,PU.1或Sp1位点的突变显著降低了Btk启动子-荧光素酶报告基因构建体的活性。此外,PU.1直接反式激活Btk启动子,而PU.1结合位点的缺失消除了这种效应。本研究表明PU.1和Sp1是Btk表达的主要调节因子,并为进一步研究缺乏Btk mRNA的XLA患者中该基因的调控奠定了基础。